trending Market Intelligence /marketintelligence/en/news-insights/trending/BMOYeoLijKQvJdT9_jyZ3Q2 content esgSubNav
In This List

Teva Pharmaceuticals faces patent infringement suit

Blog

Insight Weekly: US stock market downturn; Chinese bank earnings; Europe's big tech bills

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022


Teva Pharmaceuticals faces patent infringement suit

Aralez Pharmaceuticals Inc., two of its units and Pozen Inc. sued Teva Pharmaceuticals USA Inc., a unit of Teva Pharmaceutical Industries Ltd., for infringement of four patents covering Yosprala.

The suit, filed Jan. 23 in the U.S. District Court for the Eastern District of Texas, concerns an abbreviated new drug application filed by Teva with the U.S. FDA seeking approval to market generic versions of Yosprala prior to the expiration of the identified patents.

Three of the patents are listed in the approved drug products with therapeutic equivalence evaluations, known as the orange book, of the FDA. Pozen plans to list the fourth patent in the orange book.

Yosprala is a combination of aspirin and omeprazole, used to treat patients who need aspirin for secondary prevention of cardiovascular and cerebrovascular events and who are at risk of developing aspirin-associated gastric ulcers.